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During phase II metabolism, a substrate is rendered more hydrophilic through the covalent attachment of an endogenous
molecule. The cytosolic sulfotransferase (SULT) and UDP-glucuronosyltransferase (UGT) families of enzymes account for the
majority of phase II metabolism in humans and animals. In general, phase II metabolism is considered to be a detoxication
process, as sulfate and glucuronide conjugates are more amenable to excretion and elimination than are the parent substrates.
However,certainproductsofphaseIImetabolism(e.g.,unstablesulfateconjugates)aregenotoxic.Membersofthenuclearreceptor
superfamily are particularly important regulators of SULT and UGT gene transcription. In metabolically active tissues, increasing
evidencesupportsamajorroleforlipid-sensingtranscriptionfactors,suchasperoxisomeproliferator-activatedreceptors(PPARs),
in the regulation of rodent and human SULT and UGT gene expression. This review summarizes current information regarding
the regulation of these two major classes of phase II metabolizing enzyme by PPARs.
Copyright © 2009 M. Runge-Morris and T. A. Kocarek. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
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1.Introduction
Phase II, or conjugative, metabolism is deﬁned as the
covalent attachment of an endogenous molecule to a func-
tional group on a substrate molecule. Although a substrate
containing a suitable functional group can directly undergo
phase II metabolism, conjugation often occurs subsequent
to a phase I reaction (e.g., catalyzed by a cytochrome
P450), during which the functional group is added to the
substrate. The conjugating moiety is most often a sulfonate
or glucuronate group, although other conjugating moieties
include glutathione, glycine, acetate, and the methyl group.
Phase II metabolism usually increases the hydrophilicity of
the substrate molecule, which facilitates transport and elimi-
nation of the product. Phase II sulfonation and glucuronida-
tion reactions are catalyzed by the cytosolic sulfotransferase
(SULT) and the UDP-glucuronosyltransferase (UGT) fami-
lies of enzymes, respectively, (Figure 1). The SULT and UGT
enzymesrepresentahighlyresponsivedefensesystemagainst
the mutagenicity of carcinogenic environmental chemicals
and the toxicity of xenobiotics and endogenous metabolic
intermediates. Members of the nuclear receptor superfamily
are particularly important regulators of UGT and SULT gene
transcription. In metabolically active tissues, increasing evi-
dence supports a major role for lipid-sensing transcription
factors, such as peroxisome proliferator-activated receptors
(PPARs), in the regulation of rodent and human SULT
and UGT gene expression. This review summarizes current
information regarding the regulation of these two major
classes of phase II metabolizing enzyme by PPARs.
2. PPARs
The PPAR nuclear receptor network represents a central
determinant of cellular energy balance. In heterodimeric
partnership with the retinoid X receptor (RXR), PPAR forms
a ligand-activated nuclear receptor transcription factor that
is capable of integrating the expression of a wide spectrum
of target genes involved in cellular lipid metabolism, energy
homeostasis, and inﬂammation (Figure 2). The three known
PPAR isoforms, PPARα,P P A R δ (also called PPARβ)a n d
PPARγ are products of separate genes and are well conserved
across species. PPARα expression is the most prominent2 PPAR Research
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Figure 1: Example reactions catalyzed by PPAR-regulated SULT and UGT enzymes. The upper panel shows the SULT2A1- and
SULT2B1b-catalyzed 3-sulfonation of the prototype substrates, dehydroepiandrosterone and cholesterol, respectively. Human SULT2A1 is
transcriptionally regulated by PPARα in human hepatocytes, while SULT2B1b is regulated by PPARα,P P A R δ and PPARγ in keratinocytes.
The lower panel shows the glucuronidation of bilirubin, p-nitrophenol and hyodeoxycholic acid, which are prototype substrates for
UGT1A1, UGT1A6, and UGT2B4, respectively. UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, and UGT2B4 have all been identiﬁed
as PPAR target genes. PAPS, 3 -phosphoadenosine-5 -phosphosulfate; UDP-GA, uridine-5 -diphospho-α-D-glucuronic acid.PPAR Research 3
in the liver, kidney, and heart where it is engaged in the
regulation of fatty acid oxidation [1]. By contrast, PPARγ
is most widely expressed in adipose tissues where it plays a
role in adipocyte diﬀerentiation and the control of insulin
sensitivity [1]. PPARδ is ubiquitously expressed and has
been implicated as a regulator of a range of physiological
functions from the modulation of insulin resistance to
embryo implantation during pregnancy [1]. Fibrates and
thiazolidinedionesarewell-characterizedligand-activatorsof
PPARα and PPARγ,r e s p e c t i v e l y ,[ 1]. Fatty acids represent
a major source of cellular energy and are important phys-
iological activators of PPARα [1]. Relative to fatty acids,
oxidizedfattyacidintermediatesaremoreshort-livedspecies
a n dt h u sa r ew e l lp o i s e dt os e r v ea sb o t he n d o g e n o u s
signaling intermediates and physiological PPARγ agonists
[2]. As a key integrator of cellular energy metabolism in a
widespectrumoftissues,thePPAR·RXRtranscriptionfactor
network is being increasingly recognized for its potential
as a therapeutic target and for its expanded role in gene
regulation.
3. SULTs
3.1. The Role of SULTs in Metabolism. Sulfonation reactions
are catalyzed by two distinct families of enzymes, the
cytosolic SULTs and the membrane-bound sulfotransferases.
Of these, only the SULTs participate in phase II drug
metabolism;themembrane-boundsulfotransferasescatalyze
the sulfonation of proteins and complex carbohydrates
[3]. The SULTs catalyze the transfer of a sulfonate moiety
(SO3
−) from the physiological donor 3 -phosphoadenosine-
5 -phosphosulfate (PAPS) to a small molecule substrate con-
taining a nucleophilic moiety such as a susceptible hydroxyl
group [4]( Figure 1). The SULTs are widely expressed in
hepatic and extrahepatic tissues [5] where they represent
key components of the xenobiotic defense system. They
also function prominently in physiological processes by
metabolizing endogenous substrates, including estrogens
[6], thyroid hormones [7], bile acids [8], and neurosteroids
[9–12]. In xenobiotic metabolism, sulfate conjugation is
recognized as a double-edged sword. As a rule, sulfate con-
jugates are more polar than the parent substrate and, hence,
more amenable to excretion and elimination. However, the
production of unstable sulfate conjugates can lead to the
focused generation of genotoxic species and carcinogen
activation [13, 14].
Like other classes of xenobiotic-metabolizing enzymes,
the SULTs exist as a superfamily of related proteins with
each enzyme exhibiting a characteristic expression pattern
and substrate speciﬁcity proﬁle. The cytosolic SULTs are
categorized into two major groups, the arylsulfotransferases
(SULT1 family) and the hydroxysteroid sulfotransferases
(SULT2 family) [5, 15]. The SULT1 family is divided into
ﬁve subfamilies, designated SULT1A, SULT1B, SULT1C,
SULT1D, and SULT1E. As a brief generalization, SULT1A
subfamily enzymes metabolize phenolic substrates and func-
tion in drug metabolism. For example, SULT1A1 readily
catalyzes the sulfonation of simple phenols, such as 1-
naphthol and p-nitrophenol [4], and detoxiﬁes common
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Figure 2: Regulation of SULT and UGT gene transcription byPPARα.
The PPARα and RXR nuclear receptors are each depicted as a zinc
module-containing DNA-binding domain (rectangle) that is joined
to a ligand-binding domain (LBD, triangle) through a hinge region.
PPARα and RXR bind as a heterodimer to a peroxisome proliferator
response element (PPRE) in the regulatory region of a target gene.
The consensus PPRE is a nuclear receptor hexamer motif (i.e.,
(A/G)G(G/T)TCA) in a DR-1 conﬁguration (direct repeat with
one intervening nucleotide, N). Binding of an agonist to the LBD
of PPARα (e.g., chemical structure for the potent PPARα agonist,
ciproﬁbrate, is shown) evokes a conformational change in the
receptor that results in coactivator recruitment and increased target
gene transcription. In contrast to its silent role in partnership with
some nuclear receptors, RXR functions as an active partner with
the PPARs, whereby binding of an agonist to the LBD of RXR (e.g.,
chemicalstructurefortheprototypeRXRligand,9-cis-retinoicacid,
is shown) activates target gene transcription and enhances PPAR
ligand-activated transcription. The locations of functional PPREs
that have been identiﬁed in the 5 -ﬂanking regions of the human
SULT2A1, UGT1A1, UGT1A3, UGT1A6, UGT1A9, and UGT2B4
genes are shown (positions are relative to the transcription start
site).
phenolic pharmaceuticals, such as acetaminophen [16, 17]
and troglitazone [4]. Consistent with its role in drug
metabolism, SULT1A1 is abundantly expressed in liver,
althoughitisalsoexpressedinnumerousextrahepatictissues
[5]. Rodent enzymes of the SULT1B subfamily catalyze the
sulfonation of 3,5,3 -triiodothyronine [18], an important
step in thyroid hormone metabolism, although SULT1A1
appears to perform this function in humans [19, 20].
SULT1C enzymes are best known for their abilities to bioac-
tivate the heterocyclic amine procarcinogen, N-hydroxy-2-
acetylaminoﬂuorene, to its ultimate carcinogenic form [21].
SULT1D enzymes, described thus far chieﬂy in the canine,
sulfonate phenols, amines, and eicosanoids [22]. SULT1E1
is the physiologic estrogen sulfotransferase, catalyzing the
3-sulfonation of estradiol at nanomolar concentrations [5].
SULT1E1 is expressed most highly in tissues that are actively
engaged in estrogen metabolism, such as breast, uterus, and
placenta [23–25].
The SULT2 family is divided into two subfamilies,
SULT2A and SULT2B. In general, these SULTs most
eﬀectively metabolize molecules containing a steroid or4 PPAR Research
sterol nucleus (e.g., dehydroepiandrosterone (DHEA), preg-
nenolone, cholesterol, and bile acids) [26]. The SULT2A
subfamily members, including human SULT2A1, are most
highly expressed in liver, intestine, and adrenal cortex
[27–30], and the prototypical SULT2A substrate is DHEA
[27]( Figure 1). SULT2A-catalyzed DHEA sulfoconjugation
within the adrenal cortex provides high circulating levels of
DHEA sulfate, which serves as a reservoir of a precursor
molecule that can be converted into potent androgens and
estrogens within various tissues (e.g., prostate) [31].
The SULT2B subfamily consists of two gene products,
SULT2B1a and SULT2B1b, that are transcribed from the
same gene locus through the utilization of diﬀerent pro-
moters and incorporation of diﬀerent ﬁrst exons [11, 32,
33]. SULT2B1b preferentially catalyzes the sulfonation of
cholesterol (Figure 1), and SULT2B1b expression has been
demonstrated in skin [11, 33–35], prostate [11, 34, 36],
placenta [34, 36], lung [34, 37], intestine [11, 33, 36],
endometrium [36, 38], breast [39], ovary [36], platelets [40],
kidney [33], and muscle [11]. SULT2B1b protein has not
been detected in liver [34]. SULT2B1b has been detected in
both the cytosol and nuclei of human cells [34, 39, 41].
By comparison to SULT2B1b, SULT2B1a has minimal
activity toward cholesterol but readily catalyzes the sul-
fonation of pregnenolone [42]. Pregnenolone sulfate is a
neurosteroid that is synthesized in glial cells [43]. It is,
therefore, noteworthy that SULT2B1a mRNA expression has
been detected in brain [11]a sw e l la si nr a tC 6g l i o m a
cells [44]. However, to date SULT2B1a protein has not been
detected in any human tissues or cell lines [41].
In addition to the major SULT1 and SULT2 enzymes,
SULT3A1, SULT3A2, SULT4A1, SULT5A1, and SULT6B1
have been described [45–48] but are not highly charac-
terized. Of these, only SULT4A1 and SULT6B1 have been
identiﬁed in humans [48–50].
3.2. Regulation of SULTs by PPAR
3.2.1. Regulation of Mouse Liver SULT Expression by PPARα
Agonists. A comprehensive survey of SULT regulation by
PPARα-activating treatments has been performed by the
Klaassen research group, which evaluated the sex-dependent
regulation of hepatic SULT expression following in vivo
treatment of mice with a panel of prototypical nuclear
receptor activators, including three PPARα agonists [51].
Hepatic transcript levels were evaluated for murine SULTs
1a1, 1b1, 1c1, 1c2, 1d1, 1e1, 2a1/2a2, 2b1, and the lesser
characterized SULT family members 3a1, 4a1, and 5a1 [51].
In addition, treatment eﬀects on the mRNA expression of
both forms of PAPS synthase (PAPSs1 and PAPSs2), the
enzymes responsible for synthesizing the PAPS cofactor for
sulfate conjugation, were examined [51]. Male and female 8
week old C57BL/6 mice were treated for 4 days with either
corn oil vehicle or one of the prototypical PPARα ligands,
cloﬁbrate (500mg/kg IP), ciproﬁbrate (40mg/kg IP), or
diethylhexylphthalate (1000mg/kg IP), and euthanized for
hepatic SULT mRNA content analysis [51]. Overall, the
eﬀects of PPARα activation on murine hepatic SULT expres-
sion were not striking [51]. SULT expression in male mouse
liver was not appreciably perturbed in response to in vivo
treatment with PPARα agonists [51]. In the rat, SULT1E1,
which is more abundantly expressed in male relative to
femaleliver,waspreviouslyreportedtodecreasesubstantially
following in vivo treatment with any of the PPARα agonists,
WY-14,643, gemﬁbrozil or di-n-butylphthalate [52]. In
Klaassen’s study, the mRNA levels of several SULTs were
suppressed in female mouse liver following PPARα agonist
treatment, including SULTs 1c1, 1c2, 1e1, 2a1/2a2, 3a1, and
5a1 [51]. Treatment with cloﬁbrate increased PAPSs2 mRNA
content in male mouse liver [51]. However, such induction
was not produced by ciproﬁbrate or diethylhexylphthalate
treatment, suggesting that regulation of murine PAPSs2
expression is not an eﬀect common to PPARα agonists [51].
These studies demonstrate that PPARα activation produces
gene- and sex-dependent eﬀects on the hepatic expression of
SULT enzymes in the mouse.
3.2.2. Transactivation of Human Hepatic SULT2A1 Tran-
scription by PPARα. The above-described data suggest that
PPARα does not function as a positive regulator of murine
hepatic SULT expression. However, our laboratory has
demonstrated that human hepatic SULT2A1 expression
is increased by PPARα activation, and that this eﬀect is
conferred through a functional PPARα-response element
(PPRE) located in the distal 5 -ﬂanking region of the
SULT2A1 gene [53]. The treatment of primary cultured
human hepatocytes with ciproﬁbrate induced SULT2A1
mRNA, protein and enzyme activity levels by ∼ 2-fold [53].
This ﬁnding was in marked contrast to the rat counterpart of
SULT2A1, which was not inducible in primary cultured rat
hepatocytes following treatment with a PPARα agonist [53].
Analysis of a series of SULT2A1 5 -ﬂanking region-luciferase
reporter constructs in HepG2 cells revealed the presence of
a functional direct repeat with one intervening nucleotide
(DR-1) located at nucleotides −5949 to −5929 relative to the
transcription start site [53]( Figure 2). Further site-directed
mutagenesis, EMSA and chromatin immunoprecipitation
analyses conﬁrmed the functionality of this PPRE in the
human SULT2A1 gene [53]. These investigations reveal that
SULT2A1 represents a target for lipid signaling in human
hepatocytes and suggest that rodent models do not capture
the signiﬁcance of PPARα as a modulator of SULT2A
expression.
3.2.3. Regulation of SULT2B1b in Human Keratinocytes by
PPAR Agonists. Maintenance of the skin requires a well
orchestrated program of keratinocyte proliferation and
diﬀerentiation during which the cells pass through several
phenotypic phases identiﬁable as distinct layers (Figure 3).
As keratinocytes progress through this diﬀerentiation pro-
gram, a major change that occurs is the production of
progressively larger amounts of lipid. Cholesterol 3-sulfate
has been detected at a level of 2.4% (weight percent of total
lipids) in a combined preparation of basal/spinous cells, and
5.5% in the granular layer [54]. The amount of cholesterol
3-sulfate is then reduced in the stratum corneum, due to
the conversion of cholesterol 3-sulfate to free cholesterolPPAR Research 5
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Figure 3: Representation of keratinocyte diﬀerentiation and role of SULT2B1b-mediated cholesterol sulfonation. During formation of the
epidermis, replicating basal keratinocytes give rise to progeny that move progressively upwards and pass through several histologically
distinct strata. During this process, SULT2B1b expression becomes activated at approximately the level of the stratum granulosum.
SULT2B1b-catalyzed cholesterol sulfonation produces cholesterol 3-sulfate that, in addition to its role as a lipid component of the outer
barrier, functions as a signaling molecule that activates PKCη and possibly RORα. These signaling events result in the induction of proteins
that are involved in formation of the barrier. PPARα,P P A R δ,P P A R γ, and LXR have all been reported to positively regulate SULT2B1b
expression in cultured keratinocytes.
through the action of steroid sulfatase [54]. Cholesterol 3-
sulfate production in the lower levels of the epidermis and
its hydrolysis in the stratum corneum has been termed the
epidermal cholesterol cycle [55].
In 1984, an enzyme capable of sulfonating cholesterol
was reported to be present in mouse epidermis [56], and
several subsequent pieces of evidence have supported the
concept that “cholesterol sulfotransferase” expression and
cholesterol 3-sulfate production are events that are closely
linked to keratinocyte diﬀerentiation. For example, the spe-
ciﬁc activity of cholesterol sulfotransferase,but not of steroid
sulfatase, paralleled both the accumulation of cholesterol
3-sulfate and the formation of the multilayered structure
of the epidermis during mouse development [57, 58].
Cholesterol sulfotransferase activity was also induced during
the culture of epidermal tissues isolated from 13.5-days,
postcoitus mouse embryos with a time course that paralleled
in vitro stratiﬁcation [58]. In monolayer cultures of normal
human keratinocytes, conﬂuence-mediated diﬀerentiation
was accompanied by increased cholesterol sulfotransferase
activity and accumulation of cholesterol 3-sulfate, with
parallel increases in transglutaminase-1 [59]. Calcium-
mediated diﬀerentiation of normal human keratinocytes was
accompanied by the induction of two distinct sulfotrans-
ferase activities, cholesterol sulfotransferase, and minoxidil
sulfotransferase [60]. Exposure of fetal rat skin explants to
air caused the accelerated expression of cholesterol sulfo-
transferase along with several other markers of keratinocyte
diﬀerentiation, including ﬁlaggrin, loricrin and involucrin
[61]. A single topical administration of a tumor promoter
(e.g., phorbol ester) to mouse skin caused the induction of
cholesterol sulfotransferase, the accumulation of cholesterol
3-sulfate, and the induction of transglutaminase-1 [62, 63].
Cholesterol sulfotransferase activity was also elevated during
epidermal wound healing [62].
SULT2B1b preferentially sulfonates cholesterol and is the
chief SULT2B1 enzyme that is expressed in human ker-
atinocytes [64]. Higashi et al. [35] reported that SULT2B1b,
but not SULT2B1a or SULT2A1, was present in nor-
mal human epidermal tissue, as well as in cultures of
normal human keratinocytes following calcium-induced
diﬀerentiation. By immunohistochemistry, SULT2B1b was
largely localized to the granular layer of normal skin where
cholesterol sulfate content is highest [35]. Altogether, the
combination of substrate speciﬁcity and expression proper-
ties establish SULT2B1b as the “cholesterol sulfotransferase”
of diﬀerentiating keratinocytes [35].
In addition to its role as structural component, choles-
terol 3-sulfate is an important signaling molecule that plays
an essential role in keratinocyte diﬀerentiation (Figure 3).
For example, cholesterol 3-sulfate has been proposed to
be a physiological activator of the novel protein kinase C
(PKC) isoform, PKCη,whichislocalizedtothegranularlayer
where cholesterol sulfate concentrations are the highest [65–
67]. Activation of PKCη signals the continuance of the ker-
atinocytediﬀerentiationprogram,resultingintheexpression
of late diﬀerentiation markers, such as transglutaminase1
[65, 66, 68, 69]. In addition, it has been demonstrated that
cholesterol sulfate is a preferred ligand for the retinoid-
related orphan nuclear receptor-α (ROR-α). This nuclear
receptor, particularly the RORα4 splice variant, is robustly
expressed in the epidermis, where it is present in suprabasal
diﬀerentiating keratinocytes but not in proliferating basal
keratinocytes [70]. Until recently, RORα was considered to6 PPAR Research
be a true orphan receptor, since no ﬁrm ligand activator for
RORα had been identiﬁed. However, recent X-ray crystal-
lography data revealed the presence of either cholesterol or
cholesterol sulfate within the RORα ligand binding pocket
domain [70]. Furthermore, pharmacological manipulation
of cellular cholesterol levels altered RORα transcriptional
activity in human osteosarcoma cells [70]. These studies led
to the recognition that RORα may represent a novel regula-
tory pathway in the control of cholesterol homeostasis [71].
Compared to cholesterol, cholesterol sulfate demonstrated
ag r e a t e ra ﬃnity for the RORα ligand binding domain and
more profound eﬀects on RORα-mediated transcriptional
activation, suggesting a major role for cholesterol sulfate
as a physiologic activator of RORα in tissues such as the
epidermis where both cholesterol sulfate and RORα are
abundantly coexpressed [71, 72].
In light of the functional role of SULT2B1b in ker-
atinocyte diﬀerentiation, corneoctye desquamation and der-
mal lipid homeostasis, it is reasonable to expect that
SULT2B1b should be a target for regulation by lipid-sensing
nuclear receptors in the skin. The eﬀects, on SULT2B1b
expression, of treating cultured human keratinocytes with
chemical activators of PPARα,P P A R δ,P P A R γ, and of the
liver X receptor (LXRα and LXRβ) have been examined [73].
MeasurablelevelsofPPARandLXRtranscriptsweredetected
in cultured human keratinocytes, and the levels of PPARγ,
LXRα,a n dL X R β increased following calcium-induced dif-
ferentiation [73]. By contrast, PPARα and PPARδ mRNA
levels did not change demonstrably with keratinocyte diﬀer-
entiation [73]. Treatment with PPARα,P P A R δ,P P A R γ,a n d
LXR agonists signiﬁcantly induced SULT2B1b mRNA and
enzyme activity in cultured human keratinocytes [73]. The
PPARα agonist cloﬁbric acid increased SULT2B1b mRNA
content by ∼39.9% [73]. Activators of PPARδ (GW501516)
and PPARγ (ciglitazone) produced even greater increases (∼
9.8-fold and ∼25.1-fold, resp.) in SULT2B1b mRNA content,
and these increases were further augmented by calcium-
induced keratinocyte diﬀerentiation [73]. As modulators of
SULT2B1b expression in diﬀerentiating keratinocytes, these
results underscore the central role of PPAR transcription
factors as integrators of skin physiology and barrier function
(Figure 3).
4. UDP-Glucuronosyltransferases
4.1. The Role of UGTs in Metabolism. T h eU G T sc a t a l y z e
the transfer of glucuronic acid from a high-energy cofac-
tor, UDP-glucuronic acid, to a xenobiotic or endogenous
substrate containing an available nucleophilic center such
as a hydroxyl, carboxyl, amino, or thiol group [74–77]
(Figure 1). The UGTs are membrane-bound enzymes local-
ized on the luminal surface of the endoplasmic retic-
ulum [74]. Relative to the parent substrate, the end-
products of glucuronidation are typically more polar and
better suited for excretion and elimination through the
urine or bile [74]. Endogenous UGT substrates include
bilirubin, neutral steroids, bile acids, fatty acids, and
retinoids [74, 78, 79]. Xenobiotic UGT substrates range from
environmental toxicants such as benzo[a]pyrene to com-
mon pharmaceuticals such as acetaminophen, nonsteroidal
anti-inﬂammatory agents, ﬁbrates, thiazolidinedione-class
insulin sensitizers, and opioids [75, 78–84]. Individual UGT
enzymes display distinctive patterns of substrate speciﬁcity
and inducible regulation, but as with the SULTs, some
UGTs display overlapping substrate speciﬁcities [74, 85].
Diﬀerent UGTs are expressed in a species- and tissue-
speciﬁc manner [86, 87]. Overall, the broad metabolic
range of the UGTs distinguishes this class of conjugating
enzyme as a major detoxicating system in rodents and
humans.
Though over 50 individual UGT enzymes have been
described [86, 88], comparisons of cDNA and amino acid
sequenceshaverevealedtwomajorUGTgenefamilies,UGT1
and UGT2 [75, 86, 88, 89]. The UGT1A multigenic locus is
unusual in that it is comprised of a tandem series of thirteen
promoter regions on human chromosome 2 [75, 86, 90].
Each of nine functional UGT1A proteins is produced as a
result of transcription initiation at a particular promoter,
which results in the transcription and splicing of a unique
exon 1 sequence to a cassette of common exons (exons
2–5) that share the same 3  end [75, 86, 88, 90, 91]. As
an additional layer of complexity, recent evidence indicates
that alternative splicing events generate UGT1A isoforms
with diﬀerent exon 5 sequences. For each of these UGT1A
proteins, isoform 1 (containing exon 5a) is the classical
catalytically active enzyme, while isoform 2 (containing exon
5b) is a smaller protein that lacks UGT activity but can
inhibit the activity of the corresponding isoform 1 [92,
93]. By contrast to the UGT1A locus, UGT2 enzymes are
products of individual genes [75].
Like sulfonation, glucuronidation plays a physiological
role in the modulation of biologically active endogenous
hormones and metabolic intermediates. For example, the
activity of UGT1A1 conjugation in the tight control of
bilirubin metabolism has established the importance of
UGT1A1geneticpolymorphismsinthepathogenesisoftoxic
hyperbilirubinemias such as the Crigler-Najjar and Gilbert’s
syndromes in humans [75, 89, 94]. Thyroxine is metabolized
by O-glucuronidation in addition to deiodination and sul-
fonation [95]. Studies using recombinant UGTs and human
liver microsomes revealed that human hepatic UGT1A1
and UGT1A3 are the UGT principals most catalytically
active toward thyroxine [95]. Bile acids represent the end-
products of hepatic cholesterol metabolism and in the
absenceofsuﬃcientdetoxicationmetabolism,particularlyin
the face of cholestasis, the detergent properties of bile acids
produce signiﬁcant hepatotoxicity [96]. Human UGT2B4
[97], UGT2B7 [96, 98], UGT1A4 [96, 98], and UGT1A3 [98,
99] are all bile acid-metabolizing enzymes. The formation
of chenodeoxycholic acid (CDCA) glucuronide by UGT1A3
has been shown to decrease farnesoid X receptor (FXR)
activation by CDCA, the prototypical FXR ligand [99],
suggesting that UGT1A3 induction in human liver would be
expected to have down-stream consequences for an array of
gene expression networks that are transcriptionally regulated
by FXR.PPAR Research 7
4.2. Regulation of UGTs by PPAR.
4.2.1. Studies of the Eﬀects of Cloﬁbrate and Other Perixosome
Proliferation-Inducing Agents on UGT Activities. It has been
more than 40 years since the discovery that cloﬁbrate treat-
ment causes peroxisome proliferation in rat liver [100, 101].
After cloﬁbrate was subsequently shown to cause hepatic
induction of a unique cytochrome P450 with a reduced car-
bon monoxide-bound absorbance peak at 452nm and cat-
alytic activity toward lauric acid 12-hydroxylation, cloﬁbrate
became accepted as the prototype of a novel class of micro-
somalenzymeinducers[102]. Cloﬁbrate, therefore, was used
in a number of studies designed to evaluate the eﬀects of
microsomal enzyme inducer treatments on glucuronidation
activities. The most commonly reported ﬁnding in these
studies was that treatment with cloﬁbrate or a structurally
relatedcompoundincreasedhepaticglucuronidationactivity
toward bilirubin in rats [103–110], mice [111], and primary
cultured rat hepatocytes [112], with the cloﬁbrate-mediated
increases generally in the range of two-fold over control.
In some of these studies, use of multiple compounds
provided evidence for correspondence between induction of
rat hepatic bilirubin conjugation activity and induction of
lauric acid 12-hydroxylation [104, 105], implying probable
identity of the induction mechanism. In addition, human
subjects with Gilbert’s syndrome treated with cloﬁbrate
had decreased serum total bilirubin concentrations [113],
and hepatic microsomes prepared from humans who had
received cloﬁbrate contained elevated bilirubin UGT activity
[114].
Cloﬁbrate treatment of rats has also been reported
to increase hepatic UGT activity toward 4 -hydroxy-N,N-
dimethyl-4-aminoazobenzene [106], thyroxine and reverse
triiodothyronine [109, 115], retinoic acid [116], and the
antithrombotic drug LF 4.0212 [117]. In agreement with
these ﬁndings, cloﬁbric acid treatment also increased thy-
roxine UGT activity in primary cultured rat hepatocytes
[112]. However, a species diﬀerence in UGT induction was
suggested by the ﬁnding that cloﬁbrate treatment of male
OF-1 mice displayed no increase in hepatic microsomal thy-
roxine UGT activity [111]. Likewise, cloﬁbric acid treatment
of primary cultured mouse hepatocytes (OF-1 strain) did
not increase bilirubin or thyroxine UGT activity [112]. In
a porcine model, in vivo treatment with cloﬁbrate induced
hepatic glucuronidation of thyroid hormones suﬃciently
to reduce circulating plasma 3,3 ,5-triiodothyronine and
thyroxine concentrations [118].
Cloﬁbrate treatment has been consistently reported not
to increase UGT activity toward p-nitrophenol in rat liver
[106, 109, 110], mouse liver [111], primary cultured rat hep-
atocytes [112, 119], or primary cultured mouse hepatocytes
[112]. Cloﬁbrate treatment of rats or mice (OF-1 strain) has
also been shown to have little eﬀect on hepatic microsomal
UGT activities toward triiodothyronine and androsterone
[109, 111].
In another study, treatment of rats with a single dose of
the nonﬁbrate peroxisome proliferator, the fully-ﬂuorinated
ten-carbon fatty acid perﬂuorodecanoic acid, induced hep-
atic bilirubin UGT activity two-fold, and this induced a state
persisted for 3 weeks [120]. This single-dose treatment also
decreased hepatic UGT activities toward 1-naphthol, mor-
phine, and testosterone, with maximal reductions occurring
12 days after treatment and recovery to control activities
occurring at 3 weeks [120].
These early ﬁndings, in which peroxisome proliferator
treatments produced diﬀerential eﬀects on various UGT
activities, provided a clear indication of the multiplicity
of the UGT superfamily. As seen for the cytochromes
P450, only certain UGT activities displayed peroxisome
proliferator inducibility, predicting the later demonstration
that particular UGT genes would be targets of PPARα-
mediated transactivation.
4.2.2. UGT1A Regulation by PPARs. UGT1A1 is the major
catalystof bilirubin glucuronidation [121](Figure 1).There-
fore, based on the above-described observation that cloﬁ-
brate treatment consistently caused induction of hepatic
bilrubin UGT activity, UGT1A1 is expected to be a PPARα
targetgene,possiblyalongwithotherUGTsofthe“bilirubin-
like” portion of the UGT1A subfamily (i.e., UGTs 1A2-1A5).
In a study using antipeptide antibodies to examine
the eﬀects of drug treatments on rat hepatic microsomal
UGT levels, cloﬁbrate treatment was found to increase the
immunoreactive protein levels of UGT1A1 and UGT1A5
(termed UGT1B1 and UGT1B5 in that study) along with
bilirubin UGT activity [110]. In a more recent study,
four-day treatments of male rats with PPARα activators
producedmodestincreasesinhepaticUGT1A1andUGT1A3
mRNA levels [122]. In addition, cloﬁbric acid treatment
of primary cultured rat hepatocytes has been reported to
increase the amount of UGT1A1 protein by western blot
analysis [119] and the amount of UGT1A1 mRNA by
microarray analysis [123]. Therefore, as predicted by the
bilirubin glucuronidation activity data, UGT1A1 is a target
of PPARα activation. Cloﬁbrate treatment has also been
reported to decrease the amount of rat hepatic microsomal
UGT1A6 protein (termed UGT1A1 in that study) [110].
This ﬁnding is also in agreement with the above-mentioned
earlier ﬁnding that cloﬁbrate treatment did not induce
p-nitrophenol glucuronidation activity in rodent liver or
cultured hepatocytes, since UGT1A6 is a major catalyst of
that activity [124]( Figure 1).
InarecentstudybySenekeo-Eﬀenbergeretal.[125],Wy-
14,643 treatment of primary cultured human hepatocytes
increased the levels of UGT1A1, UGT1A3, UGT1A4, and
UGT1A6, but not UGT1A9, mRNAs. In the same study,
experiments conducted with transgenic mice engineered to
express the complete human UGT1 gene locus demon-
strated that oral Wy-14,643 treatment resulted in prominent
induction of human UGT1A1 and UGT1A6, and observable
induction of UGT1A4, immunoreactive protein content in
liver microsomes. At the mRNA level in liver, very strong
(>100-fold) induction of UGT1A1 and UGT1A3, signiﬁcant
(∼ 3- to 4-fold) induction of UGT1A4 and UGT1A6, and no
induction of UGT1A9 were seen, in general agreement with
theabove-describedeﬀectsinthehumanhepatocytecultures
[125]. In small intestine, Wy-14,643 treatment produced8 PPAR Research
induction of UGT1A1 and UGT1A4, but not UGT1A6,
while in kidney only UGT1A6 was induced [125]. Additional
experiments conﬁrmed the presence of functional PPREs in
the 5 -ﬂanking regions of UGT1A1, UGT1A3 and UGT1A6
[125]( Figure 2).
In another study, treatment of primary cultured human
hepatocytes with activators of PPARα increased the expres-
sion of UGT1A3 and UGT1A3-catalyzed glucuronidation of
chenodeoxycholic acid (CDCA) and demonstrably tempered
the transactivation of FXR by CDCA [99]. Promoter analysis
o ft h eh u m a nU G T 1 A 3g e n er e v e a l e dc o r e g u l a t i o nb yt w o
lipid-sensing transcription factors, LXR [126]a n dP P A R α
[125].
UGT1A4wasalsoidentiﬁedasasigniﬁcantlyupregulated
gene in cloﬁbric acid-treated primary cultured human
hepatocytes by Aﬀymetrix microarray analysis [123]. In this
same study, cloﬁbric acid treatment of primary cultured
mouse hepatocytes failed to cause signiﬁcant alteration
of any UGT transcripts [123], consistent with the above-
described apparent lack of sensitivity of mouse to PPARα-
mediated regulation of UGT activities.
By comparison to the results described by Senekeo-
Eﬀenberger et al. [125], Barbier et al. [78] previously
reported that mouse and human UGT1A9 are transcrip-
tionally activated by PPARα and PPARγ, and that human
UGT1A9 contains a functional PPRE located at nucleotides
−719 to −706 (Figure 2). UGT1A9 mRNA induction
was observed in primary cultured human hepatocytes
treated with fenoﬁbric acid, HepG2 cells treated with
Wy-14,643, 3T3-L1 adipocytes treated with rosiglitazone,
primary human macrophages treated with Wy-14,643, or
diﬀerentiated THP-1 macrophages treated with Wy-14,643
or rosiglitazone [78]. As expected, the inducing eﬀect of
fenoﬁbric acid on mouse hepatic UGT1A9 was ablated in
PPARα- n u l lm i c e[ 78].
4.2.3. UGT2B Regulation by PPARα. In human hepatocytes,
treatment with a PPARα agonist, fenoﬁbric acid or Wy-
14643, increased the expression of UGT2B4 mRNA and
stimulated the glucuronidation of hyodeoxycholic acid, a
model substrate for UGT2B4 [97]( Figure 1). Transient
transfection and EMSA studies revealed a functional DR-
1 PPRE at nucleotides −1199 to −1175nt relative to the
UGT2B4 transcription start site and solidiﬁed UGT2B4 as a
transcriptional target of PPARα [97]( Figure 2).
5. Regulation of SULTs and UGTs by Other
Nuclear Receptors
In addition to regulation by PPARs, the SULTs and UGTs
receive transcriptional input from multiple other nuclear
receptors. Here, we do not attempt to be comprehensive
but present several ﬁndings related to the regulation of
hepatic SULT2A expression as an example. Our previous
investigations suggested roles for both the glucocorticoid
receptor (GR) and the pregnane X receptor (PXR) in the
mediation of glucocorticoid-inducible rat hepatic SULT2A
expression [127]. GR-activating concentrations of gluco-
corticoid transactivated SULT2A transcription indirectly,
through intermediary steps involving GR-inducible liver-
enriched CCAAT enhancer binding protein [128], while
pharmacological concentrations of dexamethasone induced
rat hepatic SULT2A expression via a PXR-mediated mech-
anism [127]. Rodent and human SULT2A are diﬀerentially
regulated by the xenobiotic-sensing receptor, PXR. In mice
and rats, hepatic SULT2A transcription is activated by PXR
through the direct binding of PXR to the 5 -ﬂanking regions
of SULT2A genes [127, 129]. However, unlike rodent hepatic
SULT2As, treatment of human liver cells with rifampicin,
the prototypical ligand activator of human PXR [130],
produces a biphasic eﬀect on SULT2A1 expression [131].
Treatment with PXR-activating concentrations of rifampicin
causes PXR-dependent suppression of SULT2A1 expression,
whereas treatment with higher rifampicin concentrations
induces SULT2A1 expression through a PXR-independent
mechanism [131]. In addition, the nuclear receptor hep-
atocyte nuclear factor 4α (HNF4α) is a positive regulator
of SULT2A1 expression, and both the suppressive and
activating eﬀects of rifampicin appear to be transduced
through interactions with HNF4α [131].
The constitutive androstane receptor (CAR) also part-
ners with RXR and transactivates murine hepatic SULT2A,
and possibly human SULT2A1 [132]. The vitamin D
receptor (VDR, NR1I1) is activated not only by 1α,25-
dihydroxyvitaminD3 butalsobybileacids[133],andemerg-
ing evidence suggests that the VDR regulates murine hepatic
SULT2Atranscription,andcanalsodrivethetranscriptionof
SULT2A1 in vitro [134] .T h er o l eo fS U L T 2 Aa sa ni n t e gr a t o r
of endogenous lipid metabolism is just emerging. Oxysterol
intermediates of cholesterol metabolism are physiological
ligands for LXR, an RXR heterodimer transcription factor
thatregulatesanumberofgenesinvolvedinthemaintenance
of lipid homeostasis [135]. LXR-inducible murine hepatic
SULT2A gene transcription has been described and has
been shown to confer a protective eﬀect against bile acid
toxicity during cholestasis [136]. Certain sulfonated auto-
oxidized sterols, such as 5α,6α epoxycholesterol-3-sulfate
and 7-ketocholesterol-3-sulfate, have been shown to interact
with the LXRα ligand-binding domain and inhibit LXRα-
mediated transactivation in vitro [137]. A suppressive role
for FXR in the regulation of hepatic SULT2A expression has
also been identiﬁed, as SULT2A expression was increased 8
fold in FXR-null mice as compared to wild-type mice, and
CDCA feeding decreased SULT2A expression in wild-type
mice[138].Also,SULT2A1expressionwasreducedfollowing
treatment of HepG2 cells with FXR agonists [138].
6. Conclusions
Emerging evidence supports an under-appreciated physi-
ological role for members of the SULT and UGT gene
families to serve as modulators of biologically active lipids
andtoundergotransactivationbylipid-sensingtranscription
factors such as the PPARs. Particularly in keratinocytes
which rely on lipid signaling for the progression of pro-PPAR Research 9
grammed cellular diﬀerentiation, the inducible expression
of cholesterol sulfotransferase (SULT2B1b) by PPAR acti-
vators has been demonstrated. Studies in primary cul-
t u r e dh u m a nb u tn o tr a th e p a t o c y t e sc l e a r l yd e m o n s t r a t e
that PPARα-inducible human hepatic SULT2A1 expression
occurs through a distal PPRE in the 5 -ﬂanking region
of the SULT2A1 gene. Several human hepatic UGTs also
demonstrate inducible transcription in response to PPARα
activation, and transgenic mice expressing the human UGT1
gene locus display transcriptional regulation of human
UGT1A transgenes in liver and intestine by PPARα.I nv i e w
of the coordinated integration between phase II metabolism
and PPAR lipid signaling networks, future investigations
will likely focus on the disturbances in hepatic and gas-
trointestinal lipid homeostasis that signiﬁcantly alter SULT
and UGT expression suﬃciently to disrupt the down-stream
metabolism of environmental xenobiotics, pharmaceuticals,
or biologically active intermediates of metabolism.
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